NASDAQ:NYMX - Nymox Pharmaceutical News Headlines

$1.62
+0.09 (+5.88 %)
(As of 06/17/2019 03:26 AM ET)
Today's Range
$1.54
Now: $1.62
$1.65
50-Day Range
$1.45
MA: $1.65
$1.85
52-Week Range
$1.25
Now: $1.62
$3.90
Volume81,577 shs
Average Volume88,189 shs
Market Capitalization$109.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.94

Headlines

Nymox Pharmaceutical (NASDAQ NYMX) News Headlines

Source:
DateHeadline
Nymox Pharmaceutical: Assessing The Short And Long IdeasNymox Pharmaceutical: Assessing The Short And Long Ideas
seekingalpha.com - June 14 at 10:02 AM
Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director Acquires $13,140.00 in StockNymox Pharmaceutical Corp (NASDAQ:NYMX) Director Acquires $13,140.00 in Stock
www.americanbankingnews.com - June 12 at 11:04 AM
Nymox Pharmaceutical Corp (NYMX) Director Acquires $17,050.00 in StockNymox Pharmaceutical Corp (NYMX) Director Acquires $17,050.00 in Stock
www.americanbankingnews.com - June 6 at 2:29 PM
Nymox Pharmaceutical Corp (NYMX) Director James George Robinson Acquires 9,000 SharesNymox Pharmaceutical Corp (NYMX) Director James George Robinson Acquires 9,000 Shares
www.americanbankingnews.com - June 4 at 5:56 PM
Nymox Pharmaceutical Corp (NYMX) Director Buys $14,960.00 in StockNymox Pharmaceutical Corp (NYMX) Director Buys $14,960.00 in Stock
www.americanbankingnews.com - May 31 at 2:32 PM
James George Robinson Purchases 9,000 Shares of Nymox Pharmaceutical Corp (NYMX) StockJames George Robinson Purchases 9,000 Shares of Nymox Pharmaceutical Corp (NYMX) Stock
www.americanbankingnews.com - May 30 at 11:27 AM
Nymox Pharmaceutical Corp (NYMX) Director Buys $12,720.00 in StockNymox Pharmaceutical Corp (NYMX) Director Buys $12,720.00 in Stock
www.americanbankingnews.com - May 28 at 2:22 PM
Before You Buy Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Consider Its VolatilityBefore You Buy Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Consider Its Volatility
finance.yahoo.com - May 10 at 5:53 PM
Nymox Reports Pre-NDA CMC Meeting with the FDANymox Reports Pre-NDA CMC Meeting with the FDA
finance.yahoo.com - April 16 at 6:17 PM
Nymox Teleconference Monday, March 25 10:00 a.m. EDTNymox Teleconference Monday, March 25 10:00 a.m. EDT
finance.yahoo.com - March 21 at 6:18 PM
Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC) Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC) 
finance.yahoo.com - March 19 at 6:26 PM
Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC)Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC)
www.globenewswire.com - March 19 at 9:51 AM
Introducing Nymox Pharmaceutical (NASDAQ:NYMX), The Stock That Slid 60% In The Last Five YearsIntroducing Nymox Pharmaceutical (NASDAQ:NYMX), The Stock That Slid 60% In The Last Five Years
finance.yahoo.com - March 18 at 6:32 PM
Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Companys Manufacturing Operations - GlobeNewswireNymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Company's Manufacturing Operations - GlobeNewswire
globenewswire.com - March 15 at 9:57 AM
Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Companys Manufacturing OperationsNymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Company's Manufacturing Operations
finance.yahoo.com - March 13 at 5:55 PM
Nymox to Host Investor TeleconferenceNymox to Host Investor Teleconference
finance.yahoo.com - March 11 at 6:31 PM
Does The Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Share Price Fall With The Market?Does The Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Share Price Fall With The Market?
finance.yahoo.com - January 30 at 5:47 PM
New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment ...New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment ...
globenewswire.com - January 15 at 5:15 PM
New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in UrologyNew Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology
finance.yahoo.com - January 15 at 5:15 PM
2018: A Year of Achievements for NYMOX2018: A Year of Achievements for NYMOX
finance.yahoo.com - December 19 at 4:54 PM
Are Insiders Selling Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock?Are Insiders Selling Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock?
finance.yahoo.com - December 14 at 4:49 PM
Nymox: 3Q Earnings SnapshotNymox: 3Q Earnings Snapshot
finance.yahoo.com - November 14 at 9:07 AM
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On TrackCorporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
globenewswire.com - October 11 at 4:17 PM
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On TrackCorporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
finance.yahoo.com - October 11 at 4:17 PM
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and RadiotherapyNymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
finance.yahoo.com - October 9 at 4:17 PM
Nymox Pharma (NYMX) Announces Long-Term Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign ProstaticNymox Pharma (NYMX) Announces Long-Term Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic
www.streetinsider.com - October 4 at 9:02 AM
Nymox up 15% on fexapotide triflutate safety dataNymox up 15% on fexapotide triflutate safety data
seekingalpha.com - October 3 at 4:19 PM
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic HyperplasiaNymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
finance.yahoo.com - October 3 at 4:19 PM
Nymox: 2Q Earnings SnapshotNymox: 2Q Earnings Snapshot
finance.yahoo.com - August 14 at 9:44 AM
NYMOX Announces Expanded Marketing PlansNYMOX Announces Expanded Marketing Plans
finance.yahoo.com - July 2 at 4:08 PM
NYMOX Successfully Achieves Manufacturing Scale-UpNYMOX Successfully Achieves Manufacturing Scale-Up
finance.yahoo.com - June 7 at 4:28 PM
Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association ...Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association ...
globenewswire.com - May 23 at 4:35 PM
Nymox Pharma (NYMX) Highlights Fexapotide Triflutate Pivotal Phase 3 Study ResultsNymox Pharma (NYMX) Highlights Fexapotide Triflutate Pivotal Phase 3 Study Results
www.streetinsider.com - May 23 at 4:35 PM
Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San FranciscoFexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco
finance.yahoo.com - May 22 at 4:24 PM
Nymox: 1Q Earnings SnapshotNymox: 1Q Earnings Snapshot
finance.yahoo.com - May 16 at 9:44 AM
What You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major InvestorsWhat You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major Investors
finance.yahoo.com - May 1 at 4:23 PM
Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?
finance.yahoo.com - April 14 at 9:37 AM
Nymox Pharma (NYMX) Reports $16.25 Million Equity Financing With Qualified Long-Term InvestorsNymox Pharma (NYMX) Reports $16.25 Million Equity Financing With Qualified Long-Term Investors
www.streetinsider.com - April 12 at 4:26 PM
Nymox secures $16.25M capital raiseNymox secures $16.25M capital raise
seekingalpha.com - April 12 at 4:26 PM
Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term InvestorsNymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors
finance.yahoo.com - April 12 at 10:22 AM
New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of UrologyNew Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
finance.yahoo.com - April 10 at 4:27 PM
Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?
finance.yahoo.com - March 19 at 4:20 PM
Symposium and Panel Discussion on Nymoxs Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
finance.yahoo.com - March 1 at 4:48 PM
Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks LikeInterested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - February 28 at 9:25 AM
Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release)Nymox Announces US NDA for Fexapotide for BPH - GlobeNewswire (press release)
globenewswire.com - February 6 at 9:06 AM
Nymox Announces US NDA for Fexapotide for BPHNymox Announces US NDA for Fexapotide for BPH
finance.yahoo.com - February 5 at 4:25 PM
The Clock Is Ticking For Nymox Pharmas European Drug Application - Bet On A Rejection - Seeking AlphaThe Clock Is Ticking For Nymox Pharma's European Drug Application - Bet On A Rejection - Seeking Alpha
seekingalpha.com - February 2 at 9:08 AM
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of UrologyFexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
finance.yahoo.com - January 30 at 9:33 AM
Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. MenNymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
www.streetinsider.com - January 23 at 4:06 PM
AMGNs LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - NasdaqAMGN's LIBERTY Meets Goals, ANTH Yields RESULT, CCXI Up On Cancer Trial Data - Nasdaq
www.nasdaq.com - January 23 at 8:19 AM
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel